載入...
p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells
Paclitaxel (PTX) is a chemotherapeutic agent that is used to treat a variety of cancers, including non-small cell lung cancer (NSCLC). However, the emergence of drug resistance limits the utility of PTX. This study determined the signaling pathway that contributes to PTX resistance. We first establi...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4884985/ https://ncbi.nlm.nih.gov/pubmed/26799187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6945 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|